Fullscript

Fullscript Competitive Intelligence & Landscape

fullscript.com ·

Overview

Fullscript Overview

Fullscript is a Canadian-based digital health platform founded in 2011 that specializes in supporting healthcare providers in delivering whole person care. The company offers a comprehensive platform that integrates industry-leading labs, clinically effective supplements, and advanced tools to promote adherence and improve health outcomes (Exa, fullscript.com/about). With a workforce of approximately 575 employees, Fullscript serves over 100,000 healthcare professionals and more than 6 million patients across the United States and Canada, generating around $450 million in annual revenue (Welcome to the Jungle).

Fullscript's core services include personalized treatment planning, supplement management, and diagnostic testing, all aimed at fostering preventative and holistic healthcare practices. The company's mission is to help people get better by making preventative medicine more accessible, easier to practice for providers, and more engaging for patients. It emphasizes the importance of whole person health, focusing on prevention through diet, exercise, stress management, and clinically effective supplements (fullscript.com/about).

As a leader in health technology, Fullscript has expanded significantly through funding rounds, including a recent venture round in 2025, and has acquired other companies like Emerson Ecologics to further its mission of transforming health delivery (Nutraceuticals World). Its strategic focus is on creating an integrated, patient-centered healthcare experience that supports sustainable, preventative, and personalized medicine.

Competitors

Fullscript Competitors

ScriptSure by DAW Systems, Inc. stands out with its award-winning e-prescribing platform, emphasizing accuracy, security, and compliance, including full HIPAA adherence. It offers features like controlled substance prescribing, medication updates, and detailed cost transparency, targeting healthcare providers seeking reliable prescription management (source).

Webware.io is a notable competitor in the eCommerce and healthcare technology space, with a focus on digital marketing and online ordering solutions for health practices, though specific feature comparisons to Fullscript are less detailed (source).

InpharmD and Welldium are also key players, with InpharmD specializing in pharmacy management solutions and Welldium offering telehealth and wellness services, positioning themselves as comprehensive health tech providers that indirectly compete with Fullscript's supplement distribution and healthcare integration services (source).

Vitaminscript by Holistic Health Partners differentiates itself by providing high-quality supplements at 12-40% lower prices than Fullscript, with a focus on practitioner-direct access and personalized holistic advice, appealing to cost-conscious practitioners and patients (source).

In terms of market positioning, Fullscript is recognized for its extensive supplement catalog and integration capabilities, serving over 125,000 healthcare providers, with estimated revenue of around $94.2M and significant funding of $267M, indicating a strong market share in the practitioner supplement space (source, tracxn.com). Each competitor varies in focus, from ScriptSure’s prescription accuracy to Vitaminscript’s cost advantages, but all aim to capture segments of the healthcare and supplement distribution markets.

Alternatives

Fullscript Alternatives

Product & Pricing

Fullscript Product and Pricing Intelligence

Fullscript offers a free account option for both practitioners and patients, with no initial cost to access core features (fullscript.com). The platform emphasizes that providers and patients can join and use the service at no charge, supporting a wide range of healthcare practices and networks (fullscript.com).

While the basic account is free, Fullscript generates revenue primarily through a 10% convenience fee on supplement orders, which is lower than many competitors charging between 20-25% (leslibitel.com). The platform also offers optional paid features and tools, such as automated refill reminders, inventory management, and personalized supplement plans, aimed at enhancing practice efficiency and patient engagement (fullscript.com).

Pricing for labs and diagnostic testing is handled differently; all lab testing on Fullscript is cash-pay only, with flexible billing options including custom fees, practitioner pay, and patient pay, but no insurance reimbursement is available for these services (support.fullscript.com). Recent updates indicate that there are no tiered paid plans for the core platform, and the focus remains on free usage with optional add-ons for advanced practice needs (saasworthy.com).

Hiring & Layoffs

Fullscript Hiring and Layoffs

As of March 2026, Fullscript continues to demonstrate strong growth and active hiring, reflecting its strategic focus on expanding its healthcare technology platform. The company has recently expanded its leadership team, including new roles within its C-suite, to support ongoing growth initiatives (Fullscript blog). This leadership expansion signals a focus on scaling operations and innovating within the integrative health space.

In terms of hiring trends, Fullscript is actively recruiting for technical roles such as senior backend engineers and data scientists, emphasizing speed and quality in deployment, which aligns with their rapid development culture (Remotive; Fullscript careers). The company’s hiring patterns suggest a strategic emphasis on technological innovation, product development, and scaling their platform to serve over 125,000 practitioners and millions of patients (BounceWatch).

Regarding layoffs, there is no recent publicly available information indicating layoffs at Fullscript, which suggests the company remains focused on growth and talent acquisition. Their recent funding round in May 2025, raising $273.1 million, further supports their aggressive expansion strategy and long-term company stability (Fullscript funding). Overall, Fullscript’s hiring patterns and leadership investments signal a company committed to technological innovation and market expansion within the healthcare software industry.

Leadership

Fullscript Management and Leadership Team

The Fullscript management and leadership team includes key executives such as Kyle Braatz, the Co-founder and CEO, who has been instrumental in guiding the company's growth since its founding in 2011 (Fullscript). Kyle Braatz has a strong background in healthcare technology and strategic leadership, and he has been a driving force behind the company's expansion into the whole-person health market.

Recent leadership changes include Kyle Braatz officially becoming the CEO in 2021, after previously serving as President and Chief Revenue Officer, with co-founder Fran Towey transitioning to the role of Executive Chair and continuing as a member of the Board of Directors (Fullscript Blog). In 2023, Fullscript announced the addition of accomplished leaders such as Ashley Koch, who was appointed as Chief Financial and Strategy Officer, bringing extensive healthcare industry experience to the executive team (Fullscript Blog).

Furthermore, in 2024, Fullscript welcomed new visionary leaders to reinforce its commitment to whole-person health, signaling ongoing strategic growth and leadership expansion. The company also appointed Aimee Miller to its Board of Directors, highlighting its focus on strengthening governance and strategic oversight (Yahoo Finance). Overall, Fullscript's leadership team is characterized by experienced executives dedicated to innovation and growth in healthcare technology.

Financials

Fullscript Financial Performance, Fundraising, M&A

Fullscript has demonstrated significant financial growth and activity in recent years. The company is estimated to generate around $94.2 million in annual revenue, supported by a total funding of approximately $267 million across multiple rounds, with its latest funding round occurring in 2025 (CompWorth, Tracxn). Its valuation is not publicly disclosed, but industry estimates suggest an enterprise value ranging from $960 million to $1.4 billion (Dealroom).

In terms of fundraising, Fullscript has secured substantial capital, with a total of $267 million raised, indicating strong investor confidence and financial health. The company's growth is further evidenced by its recognition as one of Canada's Enterprise-Industry Leaders in 2025, reflecting rapid revenue growth and market impact (Fullscript Blog).

Regarding mergers and acquisitions, Fullscript recently completed the acquisition of Rupa Health, a San Francisco-based startup that facilitates laboratory testing management for practitioners. This acquisition aligns with its strategy to expand its service offerings and market reach, and it is on track to reach over $1 billion in annual revenues by 2025, according to its CEO (Ottawa Business Journal, Fullscript). Overall, Fullscript exhibits robust financial health, substantial funding, and active M&A activity, positioning it as a major player in healthcare technology.

Partnerships

Fullscript Partnerships, Clients and Vendors

Fullscript has established numerous notable partnerships, clients, and vendor relationships that significantly enhance its position in the healthcare industry. One of its key collaborations is with Oura, the maker of the popular Oura Ring, which allows biometric data from wearable devices to be integrated into clinical workflows, providing healthcare providers with real-time, personalized health insights (Fullscript). This partnership aims to improve whole-person care by combining wearable biometric data with lab results and treatment history, benefiting over 125,000 healthcare providers (BriefGlance).

In addition to the Oura partnership, Fullscript has formed alliances with technology companies such as Biocanic, Cerbo, Charmhealth, DrChrono, Healthie, Jane, Kalix, and ODX, to facilitate seamless health platform integrations that improve clinical efficiency and patient care (Fullscript). These integrations support providers in managing supplements, labs, and patient data within their existing healthcare systems. Furthermore, Fullscript's acquisition of Emerson Ecologics in 2022 has expanded its reach into integrative medicine, supporting over 70,000 healthcare professionals and more than 5 million patients, reinforcing its ecosystem of holistic health solutions (Fullscript).

Fullscript's ecosystem also includes partnerships with 3X4 Genetics, which enhances personalized care through genetic insights, enabling practitioners to tailor treatment plans based on genetic data (PR Newswire). Moreover, the platform collaborates with Elation Health to streamline supplement recommendations and improve patient adherence, further integrating its services into primary care practices (Elation Health). These strategic partnerships and integrations exemplify Fullscript’s commitment to advancing whole-person healthcare through collaborative technology and vendor relationships.

Events

Fullscript Event Participations

Based on the available search results, Fullscript actively participates in various industry events, conferences, webinars, and community initiatives to promote its platform and engage with healthcare professionals. Notably, Fullscript hosts and sponsors webinars focused on integrative medicine, whole person care, and treatment adherence, such as the webinars on metabolic health and the roots of anxiety, which are designed to educate and connect practitioners (Fullscript Webinars).

In addition, Fullscript has been involved in major industry gatherings like the Integrative Medicine and Health Symposium, where it showcases its platform's capabilities and its commitment to advancing integrative healthcare practices (Fullscript at the Integrative Medicine and Health Symposium). Furthermore, the company has organized or participated in large-scale summits, such as the Cardiometabolic Summit, which gathers industry leaders and clinicians to discuss proactive, whole person care (Financial Post).

While specific details about trade shows or community events are limited in the search results, it is clear that Fullscript maintains a strong presence in educational webinars, professional symposia, and industry summits, actively engaging with healthcare providers and industry leaders to promote its mission of improving patient care through integrative and functional medicine approaches.

Frequently Asked Questions

What does Fullscript's $273 million funding round in May 2025 signal about its near-term strategic priorities?

The May 2025 raise — bringing total funding to roughly $267–273 million — strongly supports CEO Kyle Braatz's stated target of crossing $1 billion in annual revenues in 2025, up from an estimated $94–450 million range cited across sources. The capital appears earmarked for platform scaling, M&A (as evidenced by the Rupa Health acquisition), and continued hiring of senior engineers and data scientists. The size of the round, combined with an enterprise valuation estimated at $960 million to $1.4 billion, suggests investors are pricing in a path to profitability rather than just growth.

What does Fullscript's acquisition of Rupa Health reveal about its competitive strategy against standalone lab-ordering platforms?

The Rupa Health acquisition directly closes the gap between supplement management and diagnostic testing, two workflows that previously required practitioners to toggle between separate platforms. By internalizing lab-ordering management, Fullscript makes it significantly harder for point-solution competitors like InpharmD or standalone lab platforms to peel away its practitioner base. This move mirrors the earlier Emerson Ecologics acquisition and follows a consistent pattern: Fullscript buys workflow adjacencies rather than building them, compressing the time to bundled-platform dominance.

Is Fullscript's hiring pattern in early 2026 consistent with a company preparing for an IPO or a sale, or is it still in pure growth mode?

Current hiring signals point firmly toward growth mode rather than IPO preparation or pre-sale rationalization. Fullscript is actively recruiting senior backend engineers and data scientists, expanding its C-suite (including the addition of Ashley Koch as Chief Financial and Strategy Officer in 2023 and a new board member Aimee Miller in 2024), and there are no reported layoffs. A company tightening up for an IPO or exit typically shows headcount flattening and margin discipline; Fullscript's posture — aggressive technical hiring alongside a large 2025 funding round — looks more like a company still investing to hit revenue milestones before any liquidity event.

What does the Oura Ring partnership tell us about Fullscript's product roadmap beyond supplement dispensing?

The Oura partnership is a deliberate signal that Fullscript is repositioning from a supplement dispensing platform toward a longitudinal, data-rich whole-person care record. By pulling wearable biometric data alongside lab results and treatment history into a single clinical view, Fullscript increases switching costs for its 125,000-plus practitioners — a provider who has months of integrated biometric and supplement data on patients has little incentive to migrate. It also sets up a data moat that purely transactional competitors (e.g., Vitaminscript) cannot easily replicate.

How should competitors interpret Fullscript's EHR integration strategy with partners like Cerbo, DrChrono, Healthie, and Elation Health?

Fullscript is executing a distribution-through-embedding strategy: rather than competing head-on for EHR market share, it buries its supplement and lab-ordering workflow inside the systems practitioners already use daily. Each integration — Cerbo, DrChrono, Healthie, Jane, Elation Health, and others — effectively makes Fullscript the default dispensing layer for that EHR's user base. For competitors, this means the realistic battleground is not winning practitioners away from Fullscript directly, but rather securing exclusivity with EHR vendors before Fullscript does.

What does Fullscript's free-tier pricing model combined with a 10% convenience fee reveal about its unit economics strategy?

Fullscript's zero-cost entry point is a deliberate land-and-expand play: by eliminating friction for practitioner sign-up, it maximizes the size of its prescribing network and then earns on transaction volume rather than subscription fees. At a 10% convenience fee — below the 20–25% that some competitors charge — Fullscript is pricing for share, not margin, betting that GMV scale across 125,000-plus providers will produce the revenue base needed to hit the $1 billion target. The cash-pay-only lab testing layer adds a second high-margin revenue stream that doesn't cannibalize supplement order flow.

What does the appointment of Ashley Koch as Chief Financial and Strategy Officer in 2023 suggest about Fullscript's financial maturation?

Hiring a dedicated CFO with healthcare industry experience — rather than keeping finance embedded under another executive — is a classic signal that a company is preparing its financial infrastructure for either an IPO, a large credit facility, or serious M&A activity. Given that the Rupa Health acquisition and the $273 million 2025 raise both followed Koch's appointment, the hire appears to have been groundwork for exactly that capital-intensive period. It also suggests the board wanted tighter financial governance as annual revenues approached the $1 billion threshold.

Does Fullscript's event strategy — Cardiometabolic Summit, Integrative Medicine and Health Symposium — indicate a content-led go-to-market shift or is this purely brand activity?

The event portfolio looks like a deliberate clinical-authority play rather than generic brand marketing. By convening industry leaders around specific clinical topics like cardiometabolic health and integrative medicine, Fullscript positions its platform as the infrastructure of choice for practitioners already invested in these frameworks. This mirrors how B2B SaaS companies use thought-leadership events to deepen relationships with high-value customer segments — in Fullscript's case, integrative and functional medicine practitioners who are more likely to drive high supplement order volumes than conventional primary care providers.

How does the 3X4 Genetics partnership fit into Fullscript's competitive moat, and what does it signal about personalization as a strategic vector?

Integrating genetic insights via 3X4 Genetics allows Fullscript practitioners to tailor supplement protocols to a patient's genetic profile, a capability that standard transactional dispensing platforms cannot offer. This raises the clinical complexity of the platform and makes Fullscript stickier with the functional and integrative medicine segment that values precision protocols. Strategically, it signals that Fullscript is building personalization as a durable moat — layering biometric data (Oura), genetic data (3X4), and lab data (Rupa Health) into a differentiation stack that would take a competitor years and multiple acquisitions to replicate.

What does Fullscript's acquisition of Emerson Ecologics in 2022 reveal about its supply-chain strategy relative to competitors?

The Emerson Ecologics acquisition gave Fullscript direct access to a practitioner-facing wholesale supplement distributor that already served over 70,000 healthcare professionals. This vertically integrates a meaningful portion of Fullscript's supply chain, reducing dependency on third-party distributors and improving margin control on the product side of its marketplace. For competitors like Vitaminscript, which competes on lower prices (12–40% cheaper than Fullscript by their own claim), Fullscript's vertical integration creates a structural cost and selection advantage that is difficult to match without a similar acquisition.

Is Fullscript's co-founder transition — Fran Towey moving to Executive Chair while Kyle Braatz became CEO — a governance stabilization signal or a potential overhang for corp-dev interest?

The 2021 transition, with Braatz moving from President and CRO to CEO and Towey stepping to Executive Chair, looks like an orderly founder-to-operator handoff rather than a conflict or departure. Towey remaining on the board as Executive Chair preserves institutional continuity, which typically reduces corp-dev risk around cultural integration in an acquisition scenario. For a strategic acquirer, this structure — an operator CEO with a founder backstop on the board — is generally considered a clean governance profile, assuming Towey and Braatz remain aligned on exit optionality.

What is the strategic risk in Fullscript's reliance on cash-pay-only lab testing, and does it limit addressable market expansion?

Fullscript's labs infrastructure is explicitly cash-pay with no insurance reimbursement, which structurally caps its penetration in conventional primary care and health system settings where insurance-covered diagnostics are the norm. This is not a near-term crisis — the integrative and functional medicine practitioners Fullscript primarily serves are accustomed to cash-pay models — but it does represent a ceiling on the total addressable market if the company tries to move upmarket into larger health systems or mainstream primary care networks. As Fullscript pushes toward $1 billion in revenue, this constraint will likely need to be addressed either through an insurance-billing partnership or a separate product tier.

Powered by ForesightIQ · Competitive intelligence from digital exhaust